Intercept Pharmaceuticals

Listing Websites about Intercept Pharmaceuticals

Filter Type:

Intercept Pharmaceutical, Inc.

(2 days ago) Oops! Something went wrong, please try again later.Add hoursAdd photosOops! Something went wrong, please try again later.WebsiteDirectionsContact usOops! Something went wrong, please try again later.Suggest an edit · Your business? Claim nowHomepage - Intercept Pharmaceuticalshttps://www.interceptpharma.comWebLatest News. Jan 5, 2023. Intercept Pharmaceuticals to Present at J.P. Morgan 41st Annual Healthcare Conference on January 12, 2023.

Url: Visit Now

Category:  Pharmaceutical,  Health Detail Drugs


Intercept Pharmaceuticals, Inc. (ICPT) - Yahoo!

(6 days ago) WebFind the latest Intercept Pharmaceuticals, Inc. (ICPT) stock quote, history, news and other vital information to help you with your stock trading and investing.

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Intercept Pharmaceuticals - Wikipedia

(5 days ago) Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease (or non-alcoholic steatohepatitis, NASH), cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Press Releases - Intercept Pharmaceuticals, Inc.

(5 days ago) WebJan 05, 2023. MORRISTOWN, N.J. , Jan. 05, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company …

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


State Street Cuts Stake in Intercept Pharmaceuticals (ICPT)

(9 days ago) WebIntercept Pharmaceuticals Background Information (This description is provided by the company.) Intercept is a biopharmaceutical company focused on the development and …

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Barclays PLC Increases Stock Holdings in Intercept …

(6 days ago) WebBarclays PLC boosted its position in shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT - Get Rating) by 351.8% in the third quarter, according to its most …

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Intercept Pharmaceuticals LinkedIn

(8 days ago) WebIntercept Pharmaceuticals Pharmaceutical Manufacturing Morristown, New Jersey 52,778 followers Our mission is to build a healthier tomorrow for patients with …

Url: Visit Now

Category:  Pharmaceutical,  Health Detail Drugs


Intercept Pharmaceuticals

(5 days ago) WebAt Intercept, our mission is to build a healthier tomorrow for patients with progressive non-viral liver diseases. Intercept’s lead product, obeticholic acid (OCA), is a first-in-class …

Url: Visit Now

Category:  Health Detail Drugs


ICPT Stock Price Intercept Pharmaceuticals Inc. Stock Quote (U.S

(8 days ago) WebIntercept Pharmaceuticals stock price target cut to $74 from $97 at B. Riley FBR. Nov. 20, 2020 at 7:28 a.m. ET by Tomi Kilgore.

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Intercept Pharmaceuticals - ICPT Stock Forecast, Price & News

(6 days ago) WebIntercept Pharmaceuticals has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last …

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


ICPT Intercept Pharmaceuticals, Inc. - Seeking Alpha

(6 days ago) WebA high-level overview of Intercept Pharmaceuticals, Inc. (ICPT) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and …

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Intercept Pharmaceuticals : Corporate Presentation – January 2023

(Just Now) WebAQ. 01/24. Intercept Pharmaceuticals : Corporate Presentation – January 2023. PU. 01/23. UBS Adjusts Price Target on Intercept Pharmaceuticals to $20 From …

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Intercept charts new path to NASH approval for obeticholic acid, …

(6 days ago) WebA year after the FDA handed Intercept Pharmaceuticals a disappointing ruling for its potential nonalcoholic steatohepatitis (NASH) medicine, the company thinks it's found a …

Url: Visit Now

Category:  Pharmaceutical Detail Drugs

Popular Searched

 › Hrs home health fax number

 › Johns hopkins arcade pharmacy

 › Careers in pharmaceutical companies

 › Health information management career map

 › Medical equipment risk levels

 › Dr recommendation for medical marijuana

 › Amerihealth prior auth pdf

 › Allina medical supply buffalo mn

 › Health science classroom ideas

 › Ogden regional medical center cardiologist

Recently Searched

 › Capital health plan sign in

 › Methodist hospital dallas careers

 › What medications are covered by tricare

 › Medicare guidelines for epidural injections

 › Dea drug drop off

 › Architecture standard of care

 › Northwestern university global health

 › Newton wellesley hospital parking

 › Community health group portal

 › Medicare medical supply store

FAQ about Intercept Pharmaceuticals

How much does Intercept Pharmaceuticals make?

The biopharmaceutical company earns $-91,430,000.00 in net income (profit) each year or ($2.17) on an earnings per share basis. How many employees does Intercept Pharmaceuticals have?

Should you buy Intercept Pharmaceuticals (ICPT) stock?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Intercept Pharmaceuticals in the last year. There are currently 6 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ICPT shares.

What is the upside for Intercept Pharmaceuticals (intercept) stock?

According to analysts' consensus price target of $22.10, Intercept Pharmaceuticals has a forecasted upside of 24.0% from its current price of $17.82. Intercept Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

What does a hold rating on Intercept Pharmaceuticals' stock mean?

A hold rating indicates that analysts believe investors should maintain any existing positions they have in ICPT, but not buy additional shares or sell existing shares. View ICPT analyst ratings or view top-rated stocks. What is Intercept Pharmaceuticals' stock price forecast for 2022?